How to take Lynparza? Detailed explanation of usage suggestions in the manual
Olaparib is an oral PARP inhibitor, mainly used to treat various solid tumors such as ovarian cancer, breast cancer, prostate cancer and pancreatic cancer carrying BRCA gene mutations. According to the instructions, olaparib is usually administered in tablet form, and the recommended standard dose is 300 mg twice daily. Patients should try to take it at a fixed time every day to maintain stable drug concentration in the body and obtain the best therapeutic effect.
Lynparza is not affected by food and can be taken on an empty stomach or after a meal. However, it should be noted that olaparib should be swallowed whole and should not be crushed or chewed, as this may affect the release and absorption of the drug in the body. If the patient misses a dose, he should take it as soon as possible. However, if it is close to the time of the next dose, he should skip the missed dose and should not take a double dose to compensate.
For patients with impaired hepatic and renal function, the dose may need to be adjusted on a case-by-case basis. Patients with moderate renal impairment may need to reduce the dosage to 200 mg once or twice daily; patients with severe renal impairment or severe liver function abnormalities currently lack sufficient data and are not recommended for use. In addition, during treatment with olaparib, routine blood tests and liver and kidney function tests should be performed regularly to ensure the safety of medication.
If side effects such as nausea, vomiting, fatigue, anemia or leukopenia occur during taking the medication, you should report it to your doctor in time, and the doctor will determine whether the dose needs to be adjusted or the medication needs to be suspended. Patients should strictly follow the doctor's instructions to take the medication, and should not change the dosage or stop the medication at will. Following the dosage guidelines in the instructions is of great significance for exerting the anti-tumor effect of Lynparza and prolonging the survival of patients.
Reference materials:https://www.lynparza.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)